Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MK-6552 Formulations and Food Effect in Healthy Adults
NCT06567002Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MK-6552 in narcolepsy (6 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time 0 to Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity and 5 more. Started Sep 2024; status: terminated.
02
Drugs
MK-6552
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT06567002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567002.